

CERTIFICATION REGARDING SEQUENCE LISTING

Application Number	09/812,485
Confirmation Number	1637
Filing Date	March 19, 2001
First Named Inventor	Kumagai
Examiner	Unassigned
Group Art	Unassigned
Attorney Docket No.	BEAR006CIP

ADDRESS TO:

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

I hereby certify that the enclosed Sequence Listing is being submitted in paper copy and on a computer-readable diskette, and that the content of the paper and computer readable copies are the same.

I hereby certify that the enclosed submission includes no new matter.

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815. If additional fees are required, including extensions of time, please consider this a petition therefore.

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

Name (Print/Type)	Paula A. Borden			Registration No.		42,344	
Signature	aut	25B		Date		July <u>31</u> , 2001	
Firm Name	Bozicevic, Field & Francis LLP		Addr	Address 200		00 Middlefield Road, Suite 200	
City	Menlo Park	State	California		zip	94025	
Telephone - Direct Dial	650-327-3400		Facs	Facsimile 6		650-327-3231	

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231.

	Name (Print/Type)	Barbara M. Weatherly	Signature	Mulea	Horly	Date	July 3 /, 2001
--	-------------------	----------------------	-----------	-------	-------	------	-----------------------



<110> Kumagai, Yoshina 1& Blacher, Russel Yoneda, Toshiyuki

<120> Integrin Binding Motif Containing
 Peptides and Methods of Treating Skeletal Diseases

```
<130> BEAR-006CIP

<140> 09/812,485
<141> 2001-03-19

<150> 09/641,034
<151> 2000-08-16

<160> 50
```

<170> FastSEQ for Windows Version 4.0

<210> 1 <211> 97 <212> PRT <213> Artificial Sequence <220> <223> peptidic compound

```
<210> 2
<211> 47
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
```

```
<400> 2
Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg Ile Gln His
                                    10
Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Val Lys Lys Ile Pro Ser
            20
                                25
                                                    30
Asp Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu Arg Gly Asp
                            40
<210> 3
<211> 47
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 3
Arg Gly Asp Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg
                                    10
Ile Gln His Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Val Lys Lys
                                25
Ile Pro Ser Asp Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu
                            40
<210> 4
<211> 47
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 4
Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg
Ile Gln His Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Val Lys
            20
                                25
Ile Pro Ser Asp Phe Glu Gly Ser Gly Tyr Thr Asp Arg Gly Asp
<210> 5
<211> 44
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
Arg Gly Asp Ser Pro Val Lys Ser Lys Ser Thr His Arg Ile Gln His
```

- 2 -

```
Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Val Lys Lys Ile Pro Ser
            20
Asp Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu
                            40
<210> 6
<211> 44
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 6
Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg
1
                                    10
Ile Gln His Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Val Lys Lys
Ile Pro Ser Asp Phe Glu Gly Ser Gly Arg Gly Asp
                            40
<210> 7
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 7
Arg Gly Asp Thr His Arg Ile Gln His Asn Ile Asp Tyr Leu Lys His
                                     10
Leu Ser Lys Val Lys Lys Ile Pro Ser Asp Phe Glu Gly Ser Gly Tyr
            20
                                25
Thr Asp Leu Gln Glu
        35
<210> 8
<211> 41
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 8
Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg
                                     10
Ile Gln His Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Val Lys Lys
```

20

Ile Pro Ser Asp Phe Glu Arg Gly Asp

```
<210> 9
<211> 27
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 9
Arg Gly Asp Leu Lys His Leu Ser Lys Val Lys Lys Ile Pro Ser Asp
Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu
<210> 10
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 10
Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg
                                     10
Ile Gln His Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Val Lys Lys
                                 25
            20
Ile Pro Ser Arg Gly Asp
        35
<210> 11
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 11
Arg Gly Asp Leu Ser Lys Val Lys Lys Ile Pro Ser Asp Phe Glu Gly
                 5
                                     10
Ser Gly Tyr Thr Asp Leu Gln Glu
            20
<210> 12
<211> 32
<212> PRT
<213> Artificial Sequence
<220>
```

- 4 -

<223> peptidic compound <400> 12 Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg 1 5 10 Ile Gln His Asn Ile Asp Tyr Leu Lys His Leu Ser Lys Arg Gly Asp <210> 13 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> peptidic compound <400> 13 Arg Gly Asp Val Lys Lys Ile Pro Ser Asp Phe Glu Gly Ser Gly Tyr 10 15 Thr Asp Leu Gln Glu 20 <210> 14 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> peptidic compound <400> 14 Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg 5 1 10 Ile Gln His Asn Ile Asp Tyr Leu Lys Arg Gly Asp <210> 15 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> peptidic compound <400> 15 Arg Gly Asp Ile Pro Ser Asp Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu <210> 16

```
<211> 25
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 16
Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg
Ile Gln His Asn Ile Asp Arg Gly Asp
<210> 17
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 17
Arg Gly Asp Asp Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu
                                     10
<210> 18
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 18
Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Ser Lys Ser Thr His Arg
1
Arg Gly Asp
<210> 19
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 19
Arg Gly Asp Gly Ser Gly Tyr Thr Asp Leu Gln Glu
```

```
<210> 20
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 20
Asp Ser Gln Ala Gln Lys Ser Pro Val Lys Arg Gly Asp
<210> 21
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 21
Arg Gly Asp Gly Tyr Thr Asp Leu Gln Glu
<210> 22
<211> 10
<212> PRT
<213> Artificial Sequence
<223> peptidic compound
<400> 22
Asp Ser Gln Ala Gln Lys Ser Arg Gly Asp
<210> 23
<211> 40
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 23
Arg Gly Asp Asn Asp Ile Ser Pro Phe Ser Gly Asp Gly Gln Pro Phe
                                     10
Lys Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly Pro Asp Leu Glu Gly
            20
                                25
Lys Asp Ile Gln Thr Gly Phe Ala
```

```
<210> 24
<211> 40
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 24
Asn Asp Ile Arg Gly Asp Ser Pro Phe Ser Gly Asp Gly Gln Pro Phe
                                 10
Lys Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly Pro Asp Leu Glu Gly
Lys Asp Ile Gln Thr Gly Phe Ala
       35
<210> 25
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 25
Asn Asp Ile Ser Pro Phe Arg Gly Asp Ser Gly Asp Gly Gln Pro Phe
                                    10
Lys Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly Pro Asp Leu Glu Gly
Lys Asp Ile
       35
<210> 26
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 26
Asn Asp Ile Ser Pro Phe Ser Gly Asp Arg Gly Asp Gly Gln Pro Phe
                                    10
Lys Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly Pro Asp Leu
<210> 27
<211> 45
<212> PRT
<213> Artificial Sequence
```

```
<220> .
<223> peptidic compound
<400> 27
Phe Ser Gly Asp Gly Gln Pro Phe Lys Asp Ile Pro Gly Lys Gly Glu
                                    10
Ala Thr Gly Pro Asp Leu Glu Gly Lys Asp Ile Gln Thr Gly Phe Ala
                                25
            20
Gly Pro Ser Glu Ala Glu Ser Arg Gly Asp Thr His Leu
                            40
<210> 28
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 28
Ile Pro Gly Lys Gly Glu Ala Thr Gly Pro Asp Leu Glu Gly Lys Asp
Ile Gln Thr Gly Phe Ala Gly Pro Ser Glu Arg Gly Asp Ala Glu Ser
            20
                                25
Thr His Leu
        35
<210> 29
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
Glu Ala Thr Gly Pro Asp Leu Glu Gly Lys Asp Ile Gln Thr Gly Phe
                                    10
1
Ala Gly Arg Gly Asp Pro Ser Glu Ala Glu Ser Thr His Leu
<210> 30
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
Asn Asp Ile Ser Pro Phe Ser Gly Asp Gly Gln Pro Phe Lys Asp Arg
```

- 9 -

```
Gly Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly Pro Asp Leu Glu Gly
            20
Lys
<210> 31
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 31
Gly Lys Gly Glu Ala Thr Gly Pro Asp Leu Glu Gly Lys Asp Ile Arg
                                     10
Gly Asp Gln Thr Gly Phe Ala Gly Pro Ser Glu Ala Glu Ser Thr His
                                 25
            20
Leu
<210> 32
<211> 40
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 32
Phe Ser Gly Asp Gly Gln Pro Phe Lys Asp Ile Pro Gly Lys Gly Glu
                                    10
Ala Thr Gly Arg Gly Asp Pro Asp Leu Glu Gly Lys Asp Ile Gln Thr
            20
                                 25
Gly Phe Ala Gly Pro Ser Glu Ala
        35
<210> 33
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 33
Asp Gly Gln Pro Phe Lys Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly
                 5
                                     10
```

Arg Gly Asp Pro Asp Leu Glu Gly Lys Asp Ile Gln Thr Gly Phe

```
<210> 34
<211> 25
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 34
Pro Phe Lys Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly Arg Gly Asp
Pro Asp Leu Glu Gly Lys Asp Ile Gln
<210> 35
<211> 28
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 35
Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly Arg Gly Asp Pro Asp Leu
1
                                    10
Glu Gly Lys Asp Ile Gln Thr Gly Phe Ala Gly Pro
<210> 36
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 36
Asp Gly Gln Pro Phe Lys Asp Ile Pro Gly Lys Gly Glu Ala Thr Gly
1
                                    10
Arg Gly Asp Pro Asp Leu Glu Gly Lys Asp Ile Gln Thr Gly Phe
<210> 37
<211> 28
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 37
Gly Lys Gly Glu Ala Thr Gly Arg Gly Asp Pro Asp Leu Glu Gly Lys
```

```
5
Asp Ile Gln Thr Gly Phe Ala Gly Pro Ser Glu Ala
            20 -
<210> 38
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 38
Glu Ala Thr Gly Arg Gly Asp Pro Asp Leu Glu Gly Lys Asp Ile Gln
1
Thr Gly Phe
<210> 39
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 39
Glu Ala Thr Gly Arg Gly Asp Pro Asp Leu Glu Gly Lys
<210> 40
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> peptidic compound
<400> 40
Glu Ala Thr Gly Arg Gly Asp Pro Asp Leu
<210> 41
<211> 4
<212> PRT
<213> Artificial Sequence
<220>
<223> glycosaminoglycan binding motif
```

<400> 41

```
Ser Gly Asp Gly
<210> 42
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> calcium binding motif
<400> 42
Asp Asn Asp Ile Ser Pro Phe Ser Gly Asp Gly Gln
<210> 43
<211> 12
<212> PRT
<213> Artificial Sequence
<223> calcium-binding motif
<221> VARIANT
<222> 2, 4, 6, 8, 10, 11
<223> Xaa = Any Amino Acid
<400> 43
Asp Xaa Asp Xaa Ser Xaa Phe Xaa Gly Xaa Xaa Gln
<210> 44
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> D-00001 peptide
<221> AMIDATION
<222> 15
<400> 44
Ile Pro Ser Asp Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu
<210> 45
<211> 15
<212> PRT
```

<213> Artificial Sequence

```
<220> .
<223> D-00002 peptide
<221> AMIDATION
<222> 15
<400> 45
Asp Phe Glu Gly Ser Gly Tyr Thr Asp Leu Gln Glu Arg Gly Asp
<210> 46
<211> 15
<212> PRT
<213> Artificial Sequence
<223> D-00003 peptide
<221> AMIDATION
<222> 15
<400> 46
Tyr Thr Asp Leu Gln Glu Arg Gly Asp Asn Asp Ile Ser Pro Phe
<210> 47
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> D-00004 peptide
<221> AMIDATION
<222> 15
<400> 47
Glu Arg Gly Asp Asn Asp Ile Ser Pro Phe Ser Gly Asp Gly Gln
                 5
<210> 48
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> D-00005 peptide
<221> AMIDATION
<222> 15
<400> 48
```

```
Asn Asp Ile Ser Pro Phe Ser Gly Asp Gly Gln Pro Phe Lys Asp
                5
<210> 49
<211> 23
<212> PRT
<213> Artificial Sequence
<220>
<223> D-00006 peptide
<221> AMIDATION
<222> 15
<400> 49
Thr Asp Leu Gln Glu Arg Gly Asp Asn Asp Ile Ser Pro Phe Ser Gly
                -5
                                    10
Asp Gly Gln Pro Phe Lys Asp
            20
<210> 50
<211> 4
<212> PRT
<213> peptide
<220>
<223> glycosaminoglycan binding motif
<221> VARIANT
<222> 3
<223> Xaa = Any Amino Acid
<400> 50
```

Ser Gly Xaa Gly

1